retatrutide drug retatrutide clinical trials Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Retatrutide Weight Loss Treatment Explained
Description
When will Retatrutide be available in the US
What Phase 3 results have been published for Retatrutide
Also contact your provider if you are unsure about your dose, suspect you accidentally injected into muscle, or have questions about switching between formulations
[DOI] [PubMed] [Google Scholar] 37.Huang G., Bhasin S., Pencina K., Cheng M., Jasuja R
The Sanyal Phase 2a in MASLD examined 98 adults with metabolic dysfunction-associated steatotic liver disease and 10 percent liver fat content, randomised to retatrutide or placebo over 48 weeks
